Your browser doesn't support javascript.
loading
AllergoOncology: Danger signals in allergology and oncology: A European Academy of Allergy and Clinical Immunology (EAACI) Position Paper.
Bergmann, Christoph; Poli, Aurélie; Agache, Ioana; Bianchini, Rodolfo; Bax, Heather J; Castells, Mariana; Crescioli, Silvia; Dombrowicz, David; Ferastraoaru, Denisa; Fiebiger, Edda; Gould, Hannah J; Hartmann, Karin; Izquierdo, Elena; Jordakieva, Galateja; Josephs, Debra H; Jutel, Marek; Levi-Schaffer, Francesca; de Las Vecillas, Leticia; Lotze, Michael T; Osborn, Gabriel; Pascal, Mariona; Redegeld, Frank; Rosenstreich, David; Roth-Walter, Franziska; Schmidt-Weber, Carsten; Shamji, Mohamed; Steveling, Esther H; Turner, Michelle C; Untersmayr, Eva; Jensen-Jarolim, Erika; Karagiannis, Sophia N.
Afiliação
  • Bergmann C; Department of Otorhinolaryngology, RKM740 Interdisciplinary Clinics, Düsseldorf, Germany.
  • Poli A; Neuro-Immunology Group, Department of Oncology, Luxembourg Institute of Health, Luxembourg, Luxembourg.
  • Agache I; Faculty of Medicine, Transylania University Brasov, Brasov, Romania.
  • Bianchini R; Comparative Medicine, The Interuniversity Messerli Research Institute, University of Veterinary Medicine Vienna, Medical University of Vienna, University of Vienna, Vienna, Austria.
  • Bax HJ; St. John's Institute of Dermatology, School of Basic & Medical Biosciences, Guy's Hospital, King's College London, London, United Kindgom.
  • Castells M; School of Cancer and Pharmaceutical Sciences, Guy's Hospital, King's College London, London, United Kingdom.
  • Crescioli S; Division of Allergy and Clinical Immunology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Dombrowicz D; St. John's Institute of Dermatology, School of Basic & Medical Biosciences, Guy's Hospital, King's College London, London, United Kindgom.
  • Ferastraoaru D; University of Lille, Inserm, CHU Lille, Institut Pasteur de Lille U1011-EGID, Lille, France.
  • Fiebiger E; Department of Internal Medicine/Allergy and Immunology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA.
  • Gould HJ; Division of Gastroenterology, Hepatology and Nutrition Research, Department of Medicine Research, Children's University Hospital Boston, Boston, Massachusetts, USA.
  • Hartmann K; Randall Centre for Cell and Molecular Biophysics, School of Basic & Medical Biosciences, King's College London, New Hunt's House, London, United Kingdom.
  • Izquierdo E; Medical Research Council & Asthma UK Centre in Allergic Mechanisms of Asthma, London, United Kingdom.
  • Jordakieva G; Department of Dermatology, University of Basel, Basel, Switzerland.
  • Josephs DH; IMMA, School of Medicine, Institute of Applied Molecular Medicine, CEU San Pablo University, Madrid, Spain.
  • Jutel M; Department of Physical Medicine, Rehabilitation and Occupational Medicine, Medical University of Vienna, Vienna, Austria.
  • Levi-Schaffer F; St. John's Institute of Dermatology, School of Basic & Medical Biosciences, Guy's Hospital, King's College London, London, United Kindgom.
  • de Las Vecillas L; School of Cancer and Pharmaceutical Sciences, Guy's Hospital, King's College London, London, United Kingdom.
  • Lotze MT; Department of Clinical Immunology, Wroclaw Medical University, Wroclaw, Poland.
  • Osborn G; ALL-MED Medical Research Institute, Wroclaw, Poland.
  • Pascal M; Pharmacology and Experimental Therapeutics Unit, School of Pharmacy, Faculty of Medicine, The Institute for Drug Research, The Hebrew University of Jerusalem, Jerusalem, Israel.
  • Redegeld F; Department of Allergy, La Paz University Hospital, IdiPAZ, Madrid, Spain.
  • Rosenstreich D; G.27A Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
  • Roth-Walter F; St. John's Institute of Dermatology, School of Basic & Medical Biosciences, Guy's Hospital, King's College London, London, United Kindgom.
  • Schmidt-Weber C; Department of Immunology, CDB, Hospital Clinic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Universitat de Barcelona, Barcelona, Spain.
  • Shamji M; Division of Pharmacology, Faculty of Science, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.
  • Steveling EH; Department of Internal Medicine/Allergy and Immunology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA.
  • Turner MC; Comparative Medicine, The Interuniversity Messerli Research Institute, University of Veterinary Medicine Vienna, Medical University of Vienna, University of Vienna, Vienna, Austria.
  • Untersmayr E; Center of Pathophysiology, Infectiology and Immunology, Institute of Pathophysiology and Allergy Research, Medical University Vienna, Vienna, Austria.
  • Jensen-Jarolim E; Center of Allergy & Environment (ZAUM), Technical University of Munich and Helmholtz Center Munich, German Research Center for Environmental Health, Munich, Germany.
  • Karagiannis SN; German Center for Lung Research (DZL), Munich, Germany.
Allergy ; 77(9): 2594-2617, 2022 09.
Article em En | MEDLINE | ID: mdl-35152450
ABSTRACT
The immune system interacts with many nominal 'danger' signals, endogenous danger-associated (DAMP), exogenous pathogen (PAMP) and allergen (AAMP)-associated molecular patterns. The immune context under which these are received can promote or prevent immune activating or inflammatory mechanisms and may orchestrate diverse immune responses in allergy and cancer. Each can act either by favouring a respective pathology or by supporting the immune response to confer protective effects, depending on acuity or chronicity. In this Position Paper under the collective term danger signals or DAMPs, PAMPs and AAMPs, we consider their diverse roles in allergy and cancer and the connection between these in AllergoOncology. We focus on their interactions with different immune cells of the innate and adaptive immune system and how these promote immune responses with juxtaposing clinical outcomes in allergy and cancer. While danger signals present potential targets to overcome inflammatory responses in allergy, these may be reconsidered in relation to a history of allergy, chronic inflammation and autoimmunity linked to the risk of developing cancer, and with regard to clinical responses to anti-cancer immune and targeted therapies. Cross-disciplinary insights in AllergoOncology derived from dissecting clinical phenotypes of common danger signal pathways may improve allergy and cancer clinical outcomes.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Hipersensibilidade / Neoplasias Tipo de estudo: Diagnostic_studies / Etiology_studies Limite: Humans Idioma: En Revista: Allergy Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Alemanha

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Hipersensibilidade / Neoplasias Tipo de estudo: Diagnostic_studies / Etiology_studies Limite: Humans Idioma: En Revista: Allergy Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Alemanha
...